The good safety profiles of these compounds should encourage future research to confirm the efficacy of TAAR1 agonists for the treatment of schizophrenia or other neuropsychiatric conditions (the drugs and their most relevant clinical trials are summarized in Table 1). The gene discussed is TAAR1; the disease is schizophrenia.